Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition
Inflammatory Bowel Diseases · 01.08.2025 · 31 (8) · 2184-2194
DOI: 10.1093/ibd/izae302 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 15.01.2025. Verfasst von Yael Weintraub und 31 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva 4920235, Israel. Hauptthemen laut MEDLINE: Adalimumab, Inflammatory Bowel Diseases, Crohn Disease, Anti-Inflammatory Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background and aims Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking. We assessed the therapeutic response to help close this gap.
Methods
This retrospective study involved 30 sites worldwide. Demographic, clinical, and laboratory data were collected from patients with VEO-IBD who commenced adalimumab therapy before the age of 6 years.
Results
Seventy-eight patients (37 Crohn’s disease, 26 ulcerative colitis, and 15 with IBD-unclassified) were included. Median age of IBD onset was 2.6 (1.3–4.1) years, with 30 (38.5%) patients diagnosed at age <2 years. Median age at adalimumab initiation was 4.2 (2.8-5.1) years. Adalimumab was used as second-line biologic therapy in 45 (57.7%) patients after infliximab. The median time to last follow-up was 63 (22-124) weeks. Significant improvement in clinical scores, CRP, fecal calprotectin, and weight Z-score were observed by Week 52. Adalimumab durability rates were 61.9%, 48.1%, and 35.6% after 1, 2, and 3 years, respectively. Drug discontinuation rates were not dependent on IBD type, age, prior anti-TNF exposure, or concomitant immunomodulatory treatment. Four (5.1%) patients developed serious infections, including 1 patient with TTC7A deficiency who died following adenovirus sepsis.
Conclusion
Adalimumab therapy is a viable therapeutic option in patients with VEO-IBD with an acceptable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva 4920235, Israel.
- Faculty of Medicine & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
- Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
- Department of Paediatrics, University of Medicine and Health Sciences, RCSI, Dublin 2, Ireland.
- Department of Paediatrics, University College Dublin, Dublin 4, Ireland.
- Department of Paediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic.
ORCID-Profile: Yael Weintraub, Lauren V Collen, Seamus Hussey, Elizabeth A Spencer, Kaija-Leena Kolho, Luca Scarallo, Matteo Bramuzzo, Darja Urlep, Anna-Maria Schneider, Shlomi Cohen, Dror S Shouval
Zitieren
APA
Weintraub, Y., Collen, L. V., Hussey, S., Mitrova, K., Machta, J. S., Kang, B., Granot, M., D'Arcangelo, G., Spencer, E. A., Kolho, K. L., Yeh, P. J., Sladek, M., Scarallo, L., Palomino, L., Afzal, N. A., de Laffolie, J., Miele, E., Bramuzzo, M., Olén, O., …, & Shouval, D. S. (2025). Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition. Inflammatory Bowel Diseases, 31(8), 2184-2194. https://doi.org/10.1093/ibd/izae302
Vancouver
Weintraub Y, Collen LV, Hussey S, Mitrova K, Machta JS, Kang B, et al. Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition. Inflammatory Bowel Diseases. 2025;31(8):2184-2194. doi:10.1093/ibd/izae302
BibTeX
@article{Weintraub2025,
author = {Weintraub, Yael and Collen, Lauren V and Hussey, Seamus and Mitrova, Katarina and Machta, Joseph S and Kang, Ben and Granot, Maya and D'Arcangelo, Giulia and Spencer, Elizabeth A and Kolho, Kaija-Leena and Yeh, Pai-Jui and Sladek, Malgorzata and Scarallo, Luca and Palomino, Laura and Afzal, Nadeem Ahmad and de Laffolie, Jan and Miele, Erasmo and Bramuzzo, Matteo and Olén, Ola and Russell, Richard K and Rohani, Pejman and Tzivinikos, Christos and Urlep, Darja and van Rheenen, Patrick F and de Ridder, Lissy and Yogev, Dotan and Schneider, Anna-Maria and Cohen, Shlomi and Garcia-Romero, Ruth and Dipasquale, Valeria and Uhlig, Holm H and Shouval, Dror S},
title = {Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {8},
pages = {2184--2194},
doi = {10.1093/ibd/izae302}
}
EUVIMED